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Summary 
Using a multistep polymerase chain reaction method, we have produced a construct in which 
a cDNA sequence encoding the extraceUular domain of the human 55-kD tumor necrosis factor 
(TNF) receptor is attached to a sequence encoding the Fc portion and hinge region of a mouse 
IgG1 heavy chain through an oligomer encoding a thrombin-sensitive peptide linker. This construct 
was placed downstream from a cytomegalovirus promoter sequence, and expressed in Chinese 
hamster ovary cells. A secreted protein, capable of  binding TNF and inactivating it, was produced 
by the transfected cells. Molecular characterization revealed that this soluble version of the TNF 
receptor was dimeric. Moreover, the protein could be quantitatively cleaved by treatment with 
thrombin. However, the monovalent extracellular domain prepared in this way has a greatly 
reduced TNF inhibitory activity compared with that of the bivalent inhibitor.  Perhaps because 
of its high affinity for TNF, the chimeric protein is far more effective as a TNF inhibitor than 
are neutralizing monodonal antibodies.  This molecule may prove very useful as a reagent for 
the antagonism and assay of TNF and lymphotoxin from diverse species in health and disease, 
and as a means of deciphering the exact mechanism through which TNF interacts with the 55-kD 
receptor. 
T 
he recent cloning of the 55-kD (1-3) and 75-kD (3-5) 
TNF receptors has opened the way for further studies 
of TNF effects and signal transduction. Moreover, it appears 
that truncated receptor molecules, lacking the transmembrane 
or cytoplasmic domains, are capable of interacting with TNF, 
and therefore have been isolated from urine (6, 7) and serum 
(2) as TNF inhibitors. We considered that derivatives of such 
molecules might prove useful as antagonists of TNF action 
in vivo, as high affinity ligands to be applied as the basis of 
a more sensitive assay for TNF, and as reagents to be used 
in defining the molecular interaction between TNF and its 
receptor. 
Unfortunately, truncated forms of the TNF receptor are 
highly unstable in vivo, and therefore are poor substitutes 
for antibodies as a means of antagonizing TNF action in living 
animals. The naturally occurring TNF receptor fragments 
are univalent and therefore have an avidity that is effectively 
far lower than that of a bivalent ligand.  The production of 
large quantities of a truncated receptor by recombinant means 
has, in our hands, been problematic, since the protein is pro- 
duced in an inactive and insoluble form in bacteria (Peppel, 
K., and B. Beutler, unpublished observations). This difficulty 
may arise from  the highly cysteine-rich  structure of the 
receptor-binding  domain (1, 2). When produced in roam- 
malian  cells through recombinant techniques,  the soluble 
receptor fragment is active, but produced at low levels, and 
therefore difficult to purify (Beutler, B., and T. Brown, un- 
published  observations). 
To circumvent these problems, we have engineered a chi- 
meric protein in which the extracellular domain of the TNF 
receptor, which normally engages the TNF molecule, is cova- 
lently linked to domains C.2 through CH3 of a mouse IgG1 
heavy chain.  Interposed between the two polypeptide  se- 
quences is a hexapeptide sensitive to cleavage by thrombin. 
The chimeric protein is expressed and secreted by Chinese 
hamster ovary (CHO)  1 cells. It is highly active as a TNF in- 
hibitor, is readily purified by affinity chromatography using 
an anti-mouse IgG column, and is quantitatively cleaved by 
thrombin to yield the extracellular domain in an active form. 
Materials  and Methods 
Cell Culture.  The human skin mdanoma cell  line SK MEL 109 
was grown in FM medium supplemented  with 10% FCS. CHO 
1  Abbreviations used in this paper: CHO,  Chinese hamster  ovary; CHX, 
cycloheximide; TNFR-ED, TNF receptor extracellular domain. 
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Transfected CHO ceils were grown in monolayer or spinner cul- 
tures. For production of the TNF inhibitor, CHO ceils in spinner 
culture were maintained in serum-free medium (90% F12:10% com- 
plete WRC 935; Amicon, Beverly, MA) for 3 d, after which ceils 
were removed and the conditioned medium containing the inhib- 
itor was processed. 
Cloning of a eDNA Encoding the TNF Receptor Extracellular Do- 
main.  The TNF receptor extraceilular domain (TNFR-ED) was 
cloned from total cytoplasmic RNA prepared from HL60 ceils using 
a reverse transcriptase/PCR protocol (8). Briefly, an oligonucleo- 
tide primer with the sequence cttaagcttagtactcaTGTGGTGCCT- 
GAGTCCTCAG, corresponding to the 3' end of the extraceilular 
domain, was used to direct first-strand eDNA synthesis in a total 
volume of 20/~1. The reaction was then diluted to 100/tl in PCK 
buffer (8) and a second primer with the sequence gcgcatcgaTCTGG- 
CATGGGCCTCTCCACC,  corresponding to the 5' end of the 
human TNF receptor, was added.  The reaction was subjected  to 
40 cycles of denaturation and synthesis in an automated tempera- 
ture cycler (Perkin Elmer Cetus Instrs., Norwalk, CT). The band 
corresponding to the TNFR-ED was purified by gel electropho- 
resis and ligated into the vector pGEM-3Z. 
Preparation of the Chimeric Construct.  A plasmid encoding a mu- 
rine IgG1 heavy chain eDNA was obtained from Dr. C. Haseman 
of the Howard Hughes Medical Institute. The TNFR-ED and the 
IgG heavy chain cDNAs were separately amplified by PCR using 
primers gcgcatcgaTC~ATGGGCCTCTCCACC  (correspond- 
ing to the 5' end of the TNFR-ED moiety), ggatccacgcggaaccag- 
TGTGGTGCCTGAGTCCTC (corresponding to the 3' TNFR-ED 
moiety and the thrombin cleavage site), ctggttccgcgtggatccGTC~C- 
CAGGGATIGTGGT (corresponding to the thrombin cleavage site 
and the 5' end of the IgG moiety, and attaagcattctagaTCATTTACC- 
AGGAGAGTG (corresponding to the 3' end of the IgG moiety). 
The PCR products obtained after the first synthetic PCR reac- 
tion thus carry the thrombin cleavage site on their 3' (TNFR-ED) 
and 5' (IgG) ends  (Fig.  1). The PCR products were isolated on 
a low melting point gel and slices containing the correct DNAs 
were combined and used for a second round of PCR amplification, 
using only primers corresponding to the 5' end of the TNFR-ED 
and 3' end of the IgG. This PCIL reaction effectively joins the 
TNFR-ED and the IgG through the thrombin cleavage site. 
The construct was then digested with ClaI and XbaI (encoded 
in the 5' TNFR-ED and 3' IgG primers) and ligated into the vector 
pCMV4 (9). The entire sequence was verified by dideoxynucleo- 
tide sequencing (10) on both strands. 
Assays of TNF and TNF Inhibitor Activity.  TNF inhibitor ac- 
tivity was determined through inhibition of TNF cytotoxicity to- 
ward human SK MEL 109 cells in the presence of the protein syn- 
thesis inhibitor cycloheximide (CHX). TypicaUy,  a constant amount 
of inhibitor was incubated with a series of standard concentrations 
of TNF in FM medium containing 10% FCS and CHX at a final 
concentration of 50/~g/ml. The final system volume was 150/~1. 
TNF was allowed to preincubate with the inhibitor for 1 h (Figs. 
3, 6-8) at 37~  in a 96-well microtiter plate.  50/~1 of FM con- 
taining 10% FCS and 5  x  104 SK MEL 109 cells was then added 
to each well. A further incubation was then carried out overnight 
at 37~  in a 5% CO2 incubator. At the end of the incubation 
the plate was washed and stained with crystal violet. The ceil-bound 
dye was dissolved in 40% acetic acid and staining was quantitated 
in an automatic plate reader (Intermed, Thousand Oaks, CA). All 
assays were performed in duplicate and the SE in all experiments 
was <10%.  mAbs against TNF were used for comparative pur- 
poses in some assays. One such antibody (designated mAb 1) was 
provided by Suntory, Inc. (Osaka, Japan). A second antibody (SW 
18.1; designated mAb 2) was provided by Dr. S. Wolpe (Genetics 
Institute, Cambridge, MA).  A third antibody (designated  mAb 
3) was provided by Dr. R. Schreiber (Washington University, St. 
Louis, MO). mAbs 1 and 2 neutralize human TNF, whereas mAb 
3 neutralizes mouse TNF. 
ClIO Cell Transfection.  CHO cells were cotransfected with the 
inhibitor eDNA  in  pCMV4  (pCMV4-I),  and  with  the vector 
pcDNAneo, in a 10:1 ratio, or with pcDNAneo alone,  using the 
calcium phosphate precipitation method of Chen and Okayama (11). 
Cells resistant to 1 mg/ml G418 were selected over a 3-wk period 
and pooled. Each transfection yielded ',~200-300 independent trans- 
fectants. 
Northern Blot Analysis.  Total cytoplasmic RNA was prepared 
from  transfected  CHO  cells  as  previously described  (12).  For 
Northern blot analysis the RNA was glyoxylated, resolved in a 
1.2% agarose gel,  and electroblotted onto a nylon membrane. It 
was  then  hybridized to  3zp-labeled antisense  riboprobes  corre- 
sponding to the TNFR-ED or to human glyceraldehyde-3-phosphate 
dehydrogenase.  After hybridization the blot was washed twice in 
2x  SSC at 70~  and finally in 0.1x  SSC at 70~  Blots were al- 
lowed to expose x-ray film overnight at  -80~ 
Production and Purification of the Chimeric TNF Inhibitor.  For 
production of inhibitor, ceils were incubated in serum-free medium 
(90% F12:10%  complete WRC 935) for 72 h. Ceils were then 
removed by centrifugation followed by filtration. The conditioned 
medium was then passed over a column of goat anti-mouse heavy 
chain IgG coupled to Sepharose (Sigma Chemical Co., St. Louis, 
MO). The affinity resin was then washed with a solution containing 
500 mM NaC1,  10 mM NaH2PO4  (pH 7.2), and 1 mM EDTA. 
Bound protein was eluted with a solution containing 50 mM acetic 
acid (pH 2.4) and 150 mM NaC1. 500-/~1 fractions were collected 
and neutralized by addition of 75/~1 of 1 M Tris (pH 8.0). Frac- 
tions were dot blotted onto nitrocellulose and incubated with alka- 
line phosphatase-conjugated goat anti-mouse IgG to permit de- 
tection and quantitation of the inhibitor. 
Thrombin Cleavage.  100 I~1 of column eluate containing *300 
ng pure inhibitor was mixed with 100 #1 of digestion buffer (at 
10 mM CaCI2,  10 mM MgC12, and 100 mM tris,  pH 7.0).  5 ~tl 
of a preparation containing 0.5 U of thrombin (Boehringer Mann- 
heim Biochemicals, Indianapolis,  IN) was then added and the reac- 
tion was incubated at 25~  for various periods of time. Aliquots 
were removed at intervals and the reaction was terminated by the 
addition of SDS sample buffer. 
Iodination of TNE  Human recombinant TNF was iodinated 
using the iodogen method (13). Radiolabehd TNF was separated 
from unincorporated 12si by chromatography on Sephadex  G-25 
(Pharmacia Fine Chemicals,  Piscataway, NJ). The specific activity 
of the final preparation was  104 cpm/ng TNF. 
Cross-linking of TNF to Inhibitor.  25 ng of lzsI TNF was in- 
cubated for 1 h at 37~  with 100 ng of purified inhibitor, or inhib- 
itor that had been cleaved with thrombin, in 50/~1 of buffer (25 
mM Hepes, pH 7.2, 50 mM NaC1, 0.1% BSA). Where indicated, 
2/~g of unlabeled competitor TNF was included in the reaction; 
2.5 #1 of disuccinimidylsuberate  (DSS; Pierce Chemical Co., Rock- 
ford, IL; 9.3 mg/ml in DMSO) was added and the reaction was 
incubated for 30 rain at 37~  The reaction was then terminated 
by the addition of SDS sample buffer. 
SDS-PAGE.  SDS-PAGE of the inhibitor and of mouse IgG, 
before and after thrombin cleavage, under reducing and nonreducing 
conditions, was carried out as previously described (14). Western 
blot analysis was performed after electrotransfer of the protein to 
nitrocellulose membranes. An alkaline phosphatase-conjugated goat 
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proteins. 
In Vitro  Translaa'on.  A  2.7-kb SacI fragment containing  the 
entire inhibitor cDNA was subcloned into pGEM4. After lineari- 
zation with XhoI, the plasmid was transcribed in vitro with SP6 
polymerase in the presence of mTGpppG to yield 5'-capped RNA 
transcripts. 20% of the transcription reaction was used to program 
rabbit reticulocyte lysates (Promega Corp., Madison, WI) in a stan- 
dard transhtion reaction prepared according to instructions provided 
by the manufacturer in the presence of 3sS-translabel  (ICN Bin- 
chemicals, Costa Mesa,  CA).  After synthesis,  the proteins were 
resolved by SDS-PAGE and analyzed by autoradiography. 
Results 
Construction  of  TNF  Inhibitor and  Expression  in  ClIO 
Cells.  The construct  used  to produce  a  chimeric protein, 
consisting of the TNF receptor-binding domain attached to 
the IgG heavy chain domains C.2 through C.3,  is illustrated 
in  Fig.  1 a,  and  a  schematic depiction  of the protein  itself 
in  (Fig.  1  b). 
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Figure  2.  Northern  blot  of 
TNR inhibitor mRNA produced 
by transfected CHO cells. 3/~g 
of  total  RNA  from  inhibitor- 
transfected or control CHO cells 
of each sample was separated on 
a 1.2% agarose  gel, dectroblotted 
onto nylon, and hybridized either 
to radiolabeled TNFR-ED anti- 
sense RNA (lane A) or to radio- 
labeled  glyceraldehyde-3-phos- 
phate  dehydrogenase  antisense 
RNA (lane B). Arrow indicates 
the position of the TNF inhibitor 
mRNA. 
CHO cells transfected with the construct express high levels 
of the chimeric mRNA (Fig. 2). The mRNA detected is not 
transcribed from the endogenous 55-kD receptor gene, since 
no such band is discernible  in CHO cells transfected only 
with pcDNAneo. Consistent with the fact that high levels 
of the chimeric mRNA are expressed by CHO cells, high 
levels of TNF inhibitory activity are secreted by transfected 
CHO cells (Fig.  3). 
Purification of Inhibitor by A~nity  Chromatography.  The 
TNF inhibitor could be purified to apparent homogeneity 
by passing conditioned medium from transfected CHO cell 
cultures over an  anti-mouse IgG-Sepharose column, and 
eluting the bound protein with 50 mM acetic acid, 150 mM 
b 
= 
I:I 
hu TNFR-ED 
211 aa 
Thrombin Cleavage Site 
6aa 
mu IgG Hinge+Fc 
227 aa 
Figure  1.  (a) Method used to construct the TNF inhibitor, cDNAs encoding the human TNFK-ED and the murine IgG1 heavy chain hinge and 
Fc region were separately amplified by PCK using primers that add unique restriction enzyme sites (ClaI on the 5' end of the TNFK-ED and XbaI 
on the 3' end of the IgG1) and a thrombin sensitive peptide linker (on the 3' end of the TNFK-ED and on the 5' end of the IgG). After separation 
of the PCR products by low melting point agarose electrophoresis, slices  containing the fragments of interest were combined and subjected to a second 
round of amplification using only the 5' end primer for RNFK-ED and the 3' end primer for IgG. The PCR products were again separated by agarose 
electrophoresis and the fragment corresponding to the full-length inhibitor was isolated, digested with ClaI and XbaI, and subcloned into pCMV4. 
CMV, cytomegalovirus promoter; 5' UTK, 5' untranslated region; T.C.S., thrombin cleavage site; hGH 3'UTK, human growth hormone 3' untrans- 
lated region; SV40 ori +  enh, simian virus 40 origin of replication and enhancer. (b) Schematic depiction of the protein. Nerve growth factor receptor- 
like cysteine-rich  domains of the TNFR-ED are represented by loops. The bars represent the cysteine  residues (oxidation state is unknown).  IgG moiety 
is presented according to the same scheme. 
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Figure 3.  Inhibition of TNF cytotoxicity by secreted inhibitor.  50 #1 
of CHO-conditioned culture medium (either from cells permanently trans- 
fected with the TNF inhibitor eDNA or from control cells transfected 
with pcDNAneo  alone) was incubated with varying amounts of human 
TNF (concentration indicated) in the presence of cycloheximide. After a 
1-h incubation at 37~  5  x  104 SK MEL 109 cells were added to the 
system, and the incubation was continued overnight.  Cell survival was 
quantitated  by staining with crystal violet. 
NaCI. Material so eluted was highly active as a TNF inhib- 
itor. Purified preparations of the inhibitor migrate at a rate 
consistent with a dimeric structure when subjected to PAGE 
under nonreducing conditions. When reduced, a monomeric 
structure is apparent (Fig. 4). The monomer is approximately 
Figure 5.  Cleavage  of the TNF inhibitor  by thrombin. Affanity-purified 
TNF inhibitor  or anti-TNF mAb 1 was digested with thrombin  for varying 
lengths of time (indicated) and separated  by nonredudng  SDS-PAGE.  After 
blotting onto a nitrocellulose membrane, the IgG-containing  fragments 
were visualized using an affinity-purified goat anti-mouse IgG antibody 
conjugated to alkaline phosphatase (Biorad Laboratories, Richmond, CA). 
Roman numerals I, II, and III refer, respectively, to the undigested form 
of the TNF inhibitor, and to forms from which one or both TNFR-ED 
have been removed by the action of thrombin. IgG remains undigested 
in the presence of thrombin. 
Figure 4.  Purification  of the 
TNF inhibitor by af~nity chroma- 
tography.  Conditioned medium 
from CHO cells transfected with 
the  TNF  inhibitor cDNA  was 
passed over a goat anti-mouse IgG 
sepharose  column.  The  bound 
protein was eluted with a solution 
containing  50 mM acetic acid and 
150 mM NaC1. The eluate was 
quickly neutralized by adding 0.1 
vol of 1 M tris, pH 8.0. Inhibitor 
so purified was subjected to re- 
ducing  (+  B-mercaptoethanol) 
and  nonreducing  (-/~-mercap- 
toethanol) SDS-PAGE.  200 ng of 
an anti-TNF mAb 1 was added to 
the gel as an additional standard. 
The gel was silver stained. 
Figure 6.  Cross-linking of TNF and inhibitor.  Lane a, 12si TNF not 
cross-linked; lane b, t2Sl TNF cross-linked with disuccinimidylsuberate; 
lane c, 12si  TNF cross-linked to inhibitor; lane d, same as lane c but unla- 
beled TNF was included as competitor;  lane e, 12sI TNF cross-linked to 
thrombin digested inhibitor; lane f, same as lane e but unlabeled TNF 
was included as competitor. 
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Figure 7.  Inhibition of TNF cytotoxicity  by inhibitor or extracellular 
domain. 600 pM of inhibitor or 600 pM of inhibitor deaved  with thrombin 
was incubated with different amounts of TNF (indicated) in the presence 
of CHX for 1 h at 37~  5 x  104 SK MEL 109 cells were added to each 
well and incubated overnight. Thrombin alone does not effect survival 
of SK MEL 109 cells in this assay (data not shown). Cell survival was 
quantitated by staining with crystal violet. 
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Figure 8.  Comparison  ofanti-TNF activity  of two mAbs against TNF 
with the activity of the TNF inhibitor. Varying amounts of antibody or 
TNF inhibitor were  incubated  with human TNF (300 pg/ml) in the pres- 
ence of CHX for 1 h at 37~  5  x  104 SK MEL 109 cells were then 
added to the system, and the incubation was continued overnight. Cyto- 
toxicity was quantitated by staining with crystal violet. 
8-10 kD larger than a protein translated from in vitro tran- 
scribed RNA (data not shown). This likely reflects glycosyl- 
ation at the three N-linked glycosylation sites of the extracel- 
lular  domain  of the TNF  receptor as identified by several 
groups (1, 2). Loetscher et al. (15) reported that TNF receptor 
isolated from HL60 cells contains 5-10 kD of carbohydrate. 
Cleavage of Inhibitor by Thrombin Reduces its Anti-TNF Ac- 
tivity.  The inhibitor is quantitatively cleaved by thrombin, 
as indicated by the fact that the heavy chain fragment visible 
on SDS-PAGE migrates faster (consistent with proteolysis at 
the thrombin-sensitive site) after incubation with this enzyme 
(Fig.  5). 
To see whether the cleaved inhibitor was still able to bind 
TNF,  we cross-linked radioiodinated TNF to inhibitor,  or 
to inhibitor  that  had been cleaved with  thrombin  and ad- 
sorbed to anti-IgG sepharose (to remove the IgG portion of 
the inhibitor  and any undigested, bivalent inhibitor).  Both 
the digested (Fig. 6, lane e) and the undigested (Fig. 6, lane 
c) preparation of the inhibitor are capable of binding TNF. 
The binding was completely abrogated by the addition  of 
80-fold excess unlabeled TNF (Fig.  6, lanes d and j~.  The 
purified inhibitor  is very effective in neutralizing  TNF.  A 
threefold molar excess of inhibitor over TNF trimer is capable 
of more than  doubling  survival of SK MEL  109 ceils in a 
standardized cytotoxic assay (Fig.  7). A 10-fold excess of in- 
hibitor over TNF trimer affords virtually complete protec- 
tion. However, cleavage with thrombin greatly reduces the 
TNF inhibitory activity of the molecule (Fig.  7).  See Dis- 
cussion for possible explanations. 
Comparison of  Anti-TNF Activity of  lnhibitor and mAbs.  To 
compare the anti-TNF  activity of the chimeric bivalent in- 
hibitor with the anti-TNF activity of three mAbs known to 
neutralize human (mAbs 1 and 2) or murine (mAb 3) TNF, 
a series  of dilutions of each reagent was used to block the 
activity of a fixed concentration of human or murine TNF 
sufficient to cause lysis of >75% ofSK MEL cells. The TNF 
inhibitor  is ,,o100- and 10,000-fold more effective than  the 
anti-TNF  mAbs  1 and 2,  respectively, as an antagonist  of 
human TNF activity (Fig.  8). The inhibitor  is also ,vl00- 
fold more  active  against  murine  TNF  than  mAb  3  (not 
shown). 
Discussion 
The TNF inhibitor that we have produced and character- 
ized finds precedent in the work of Capon et al.  (16)  and 
Traunecker et al. (17), who designed secreted chimeric mole- 
cules in which the binding moiety of a CD4 molecule was 
adjoined to an IgG heavy chain. This molecule circulated for 
a prolonged period of time in vivo.  It would thus  appear 
that adding an IgG heavy chain as a partner in chimeric mol- 
ecules may be a useful strategy for the expression of mole- 
cules that would otherwise prove unstable in circulation. The 
TNF inhibitor may prove useful under many circumstances. 
Since the molecule is produced by CHO cells in considerable 
abundance, and since it can easily be purified, it will be pos- 
sible to produce large quantities of the protein for investiga- 
tional use. Whereas a mouse IgG molecule was used in these 
studies, a homologous construct utilizing  the human  IgG 
heavy chain could readily be prepared. 
The striking efficacy of the inhibitor may result from sev- 
eral of its properties. Engdmann et al. (18) demonstrated that 
polyclonal antiserum  raised against  soluble TNF receptors 
can mimic the cytotoxic activity of TNF in the presence of 
CHX and can also reproduce a variety of other responses 
ascribed to TNF. The authors were able to show that cross- 
linking  of TNF receptors on the cell surface by antibodies 
was both necessary and sufficient to induce lysis in sensitive 
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of TNF receptors by TNF is the primary mode of signal trans- 
duction. Smith and Baglioni (19) have shown the trimer to 
be the active form of TNF. Mutagenesis studies have shown 
the subunit interface to be involved in receptor binding (20). 
Therefore, only a trimer, but not a dimer or a monomer, 
would allow the binding of the two or three receptors neces- 
sary for signal transduction. The inhibitor produced in this 
study utilizes two TNFR-EDs, and possibly blocks two of 
the three potential receptor binding sites of TNF.  In addi- 
tion, simultaneous attachment of the two binding domains 
of the inhibitor to the same trimer increases the effective affinity 
of this molecule for its ligand.  Interestingly, we find that 
cleavage of the inhibitor with thrombin greatly reduces the 
TNF inhibitory activity. The monovalent extracellular do- 
main is only able to block one of the three receptor binding 
domains of TNF; therefore, it is unable to prevent receptor 
crosslinking by the remaining free binding sites. 
The affinity of the interaction between TNF and the com- 
bining site of soluble TNF receptors has been estimated by 
several laboratories, and assigned a K, value between 109 and 
101~ (6,  7,  21, 22).  Since antibodies typically exhibit com- 
bining group affinities in the range of 10s-106 K~, it might 
be expected that the chimeric protein produced in this study 
would form far more stable complexes. The sensitivity of a 
RIA is generally limited by ligand affinity; therefore, the in- 
hibitor might permit the assay of TNF at lower concentra- 
tions than could be achieved using a competitive ILIA using 
antibodies. Moreover, the chimeric protein that we have pro- 
duced should be a particularly versatile reagent, insofar as 
it should detect TNF from a wide range of mammalian spe- 
cies, whereas most antibody preparations crossreact weakly 
with TNF from diverse species. 
Given the fact that both lymphotoxin (TNF-~) and TNF 
are bound by the 55-kD receptor with comparable affinity 
(1-5), the reagent used in these studies should effectively  neu- 
tralize both of these molecules. This property might lend 
certain advantages to the use of this inhibitor as a tool for 
the investigation of TNF function in vivo,  and as a means 
of neutralizing TNF activity for clinical effect. Insofar as the 
reagent should only recognize functional TNF (i.e., a TNF 
trimer capable of engaging its receptor), it may be imagined 
that the protein might permit an analysis of plasma concen- 
trations of active TNF (in contrast with TNF that has been 
bound by inhibitors or denatured) in various disease processes. 
Preliminary studies indicate that the inhibitor has a long 
half-life in vivo (data not shown). Therefore, it might be useful 
as a means of assessing the function of TNF under a variety 
of physiologic and pathologic conditions. Whether intermit- 
tently injected, chronically administered via a system similar 
to that described by Oliff et al. (23), who used CHO cells 
as a vehicle for the production of recombinant TNF in nude 
mice, or produced in transgenic animals, the inhibitor might 
yield valuable insight into the actions of TNF in vivo.  Of 
particular interest might be the effect of the inhibitor upon 
the course of septic shock, of tumor growth in vivo, and 
development of the immune system. It would seem likely 
that the reagent described here will prove useful as a means 
of defining the interactions that occur between TNF and its 
receptors. The TNFR-ED can easily be purified after thrombin 
cleavage. Efforts to crystallize the purified molecule and the 
thrombin cleavage product, alone and as a complex with the 
TNF molecule, are in progress. 
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